Jenny Wai

1.1k citations

18 papers · 778 indexed · h-index 14

Molecular Biology
Organic Chemistry top 10%
Oncology
Infectious Diseases top 10%
Computational Theory and Mathematics top 5%

Co-authors: Wayne J. Thompson M. Katharine Holloway Dong-Mei Feng Roger Freidinger Thomas A. Halgren Paula M.D. Fitzgerald Joseph P. Vacca Rhonda B. Levin
Topics: HIV/AIDS drug development and treatment (7 papers)Click Chemistry and Applications (4 papers)Prostate Cancer Treatment and Research (4 papers)
Cited by: Biological Psychiatry Virology Organic Chemistry
Journals: Journal of the American Chemical Society Nature Medicine Journal of Medicinal Chemistry
Partner nations: United States Japan

In The Last Decade

Jenny Wai

18 papers receiving 739 citations

Peers

Countries citing papers authored by Jenny Wai

Since Specialization

Citations

This map shows the geographic impact of Jenny Wai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jenny Wai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jenny Wai more than expected).

Fields of papers citing papers by Jenny Wai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jenny Wai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jenny Wai. The network helps show where Jenny Wai may publish in the future.

Co-authorship network of co-authors of Jenny Wai

This figure shows the co-authorship network connecting the top 25 collaborators of Jenny Wai. A scholar is included among the top collaborators of Jenny Wai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jenny Wai. Jenny Wai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species 2018 ·Bioorganic & Medicinal Chemistry Letters ·Shawn J. Stachel,Melissa S. Egbertson,Jenny Wai,Michelle R. Machacek,Dawn Toolan,John Swestock,Donnie Eddins,(unknown),Georgia B. McGaughey,Hua-Poo Su,(unknown),Deping Wang,Lei Ma,Gopal Parthasarathy,John C. Reid,Pravien Abeywickrema,Sean M. Smith,Jason M. Uslaner	3
2	Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase 2018 ·European Journal of Medicinal Chemistry ·(unknown),James B. DuHadaway,Khoa Pham,Ariel Lewis-Ballester,(unknown),Jenny Wai,(unknown),Syun‐Ru Yeh,George C. Prendergast,Alexander J. Muller,William P. Malachowski	42
3	O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1 2015 ·European Journal of Medicinal Chemistry ·William P. Malachowski,(unknown),James B. DuHadaway,Ariel Lewis-Ballester,(unknown),Jenny Wai,(unknown),(unknown),Judith M. LaLonde,Syun‐Ru Yeh,George C. Prendergast,Alexander J. Muller	33
4	Amidine derived inhibitors of acid-sensing ion channel-3 (ASIC3) 2009 ·Bioorganic & Medicinal Chemistry Letters ·Scott D. Kuduk,Ronald K. Chang,Jenny Wai,Christina N. Di Marco,(unknown),Robert M. DiPardo,Sean P. Cook,Matthew J. Cato,Aneta Jovanovska,Mark O. Urban,Michael Leitl,Robert H. Spencer,Stefanie A. Kane,George D. Hartman,Mark T. Bilodeau	45
5	A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity 2007 ·Bioorganic & Medicinal Chemistry Letters ·Dong-Mei Feng,Robert M. DiPardo,Jenny Wai,Ronald K. Chang,Christina N. Di Marco,Kathy Murphy,Richard W. Ransom,Duane R. Reiss,Cuyue Tang,Thomayant Prueksaritanont,Douglas J. Pettibone,Mark G. Bock,Scott D. Kuduk	15
6	2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists 2005 ·Bioorganic & Medicinal Chemistry Letters ·Dong-Mei Feng,Jenny Wai,Scott D. Kuduk,Christina Ng,Kathy Murphy,Richard W. Ransom,Duane R. Reiss,Raymond S.L. Chang,C. Meacham Harrell,Tanya MacNeil,Cuyue Tang,Thomayant Prueksaritanont,Roger Freidinger,Douglas J. Pettibone,Mark G. Bock	23
7	2,3-Diaminopyridine Bradykinin B₁ Receptor Antagonists 2004 ·Journal of Medicinal Chemistry ·Scott D. Kuduk,Christina Ng,Dong-Mei Feng,Jenny Wai,Raymond S.L. Chang,C. Meacham Harrell,Kathy Murphy,Richard W. Ransom,Duane R. Reiss,Magnus Ivarsson,G.S. Mason,Susan Boyce,Cuyue Tang,Thomayant Prueksaritanont,Roger Freidinger,Douglas J. Pettibone,Mark G. Bock	34
8	Design and Synthesis of a Pro-Drug of Vinblastine Targeted at Treatment of Prostate Cancer with Enhanced Efficacy and Reduced Systemic Toxicity 2002 ·Journal of Medicinal Chemistry ·Stephen F. Brady,Joseph Pawluczyk,Patricia K. Lumma,Dong-Mei Feng,Jenny Wai,Raymond C. F. Jones,Deborah Defeo-Jones,Bradley K. Wong,Cynthia Miller‐Stein,Jiunn H. Lin,Allen Oliff,Roger Freidinger,Victor M. Garsky	43
9	A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo. 2002 ·PubMed ·Deborah Defeo-Jones,Stephen F. Brady,Dong-Mei Feng,(unknown),(unknown),Kathleen Haskell,DAVID M. KIEFER,Karen Leander,Elizabeth McAvoy,Patricia K. Lumma,Joseph Pawluczyk,Jenny Wai,Sherri L. Motzel,Kevin J Keenan,(unknown),Jiunn H. Lin,Victor M. Garsky,Roger Freidinger,Allen Oliff,Raymond E. Jones	33
10	The Synthesis of a Prodrug of Doxorubicin Designed to Provide Reduced Systemic Toxicity and Greater Target Efficacy 2001 ·Journal of Medicinal Chemistry ·Victor M. Garsky,Patricia K. Lumma,Dong-Mei Feng,Jenny Wai,Harri G. Ramjit,Mohinder K. Sardana,Allen Oliff,Raymond E. Jones,Deborah Defeo-Jones,Roger Freidinger	70
11	A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo 2000 ·Nature Medicine ·Deborah Defeo-Jones,Victor M. Garsky,Bradley K. Wong,Dong-Mei Feng,(unknown),Kathleen Haskell,DAVID M. KIEFER,Karen Leander,Elizabeth McAvoy,Patricia K. Lumma,Jenny Wai,(unknown),Sherri L. Motzel,Kevin J Keenan,(unknown),Jiunn H. Lin,Roger Freidinger,Joel R. Huff,Allen Oliff,Raymond E. Jones	127
12	A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site 1995 ·Journal of Medicinal Chemistry ·M. Katharine Holloway,Jenny Wai,Thomas A. Halgren,Paula M.D. Fitzgerald,Joseph P. Vacca,Bruce D. Dorsey,Rhonda B. Levin,Wayne J. Thompson,(unknown)	178
13	Novel conformationally constrained HIV-1 protease inhibitors: rational design, enzyme inhibition, and X-ray structure of an enzyme-inhibtor complex 1994 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Joseph P. Vacca,Paula M.D. Fitzgerald,Paul L. Darke,M. Katharine Holloway,James P. Guare,(unknown),(unknown),Joan A. Zugay,Jenny Wai,Paul Anderson,Joel R. Huff	3
14	Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands 1993 ·Journal of Medicinal Chemistry ·Arun K. Ghosh,Wayne J. Thompson,M. K. HOLLOWAY,S. P. MCKEE,(unknown),Hye Young Lee,(unknown),Anthony M. Smith,Jenny Wai,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	56
15	3'-Tetrahydrofuranylglycine as a novel, unnatural amino acid surrogate for asparagine in the design of inhibitors of the HIV protease 1993 ·Journal of the American Chemical Society ·Wayne J. Thompson,Arun K. Ghosh,M. Katharine Holloway,Hee Yoon Lee,(unknown),(unknown),Jenny Wai,Paul L. Darke,(unknown)	31
16	ChemInform Abstract: Potent HIV Protease Inhibitors: The Development of Tetrahydrofuranylglycines as Novel P2‐Ligands and Pyrazine. Amides as P3‐Ligands. 1993 ·ChemInform ·Arun K. Ghosh,Wayne J. Thompson,M. K. HOLLOWAY,S. P. MCKEE,Tien T. Duong,(unknown),(unknown),Anthony M. Smith,Jenny Wai,Paul L. Darke,Joan A. Zugay,Emilio A. Emini,William A. Schleif,Joel R. Huff,Paul Anderson	2
17	A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity 1992 ·Journal of Medicinal Chemistry ·Thomas J. Tucker,William C. Lumma,Linda S. Payne,Jenny Wai,(unknown),Elizabeth A. Giuliani,Paul L. Darke,Jill C. Heimbach,Joan A. Zugay	39
18	ChemInform Abstract: A Series of Potent HIV‐1 Protease Inhibitors Containing a Hydroxyethyl Secondary Amine Transition State Isostere: Synthesis, Enzyme Inhibition, and Antiviral Activity. 1992 ·ChemInform ·Thomas J. Tucker,William C. Lumma,Linda S. Payne,Jenny Wai,(unknown),(unknown),Paul L. Darke,Jill C. Heimbach,Joan A. Zugay,William A. Schleif,J C Quintero,Emilio A. Emini,Joel R. Huff,Paul Anderson	1

About Jenny Wai

Jenny Wai is a scholar working on Biological Psychiatry, Virology and Infectious Diseases, having authored 18 papers that have together received 778 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (7 papers), Click Chemistry and Applications (4 papers) and Prostate Cancer Treatment and Research (4 papers). The work is most often cited by research in Biological Psychiatry (62 citations), Virology (67 citations) and Organic Chemistry (227 citations). Jenny Wai has collaborated with scholars based in United States and Japan. Frequent co-authors include Wayne J. Thompson, M. Katharine Holloway, Dong-Mei Feng, Roger Freidinger, Thomas A. Halgren, Paula M.D. Fitzgerald, Joseph P. Vacca, Rhonda B. Levin, Bruce D. Dorsey and Deborah Defeo-Jones. Their work appears in journals such as Journal of the American Chemical Society, Nature Medicine and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact